Management of Type 2 Diabetes – What’s New?
Summary
- Sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists benefits in cardiovascular and renal outcomes
- Canagliflozin and Diabetic Kidney disease (DKD) licence extension
- Semaglutide, the first oral GLP-1 receptor agonist